slide 1
Кирил Николчев, България

Генерален мениджър, Абви ЕООД

Иновацията във фармацията има смисъл само, когато достига до нуждаещите се от нея. Ние #НямаДаСпрем докато достиженията на науката не станат достъпни за българските пациенти.

slide 1
Деян Денев, България

Изпълнителен директор, ARPharM

През следващите години фармацевтичната индустрия ще разработи нови терапии за нерешените проблеми в онкологията, диабета, хемофилията, болест на Алцхаймер, инфекциите, чернодробни заболявания, мигрената. Ние #НямаДаСпрем, докато не осигурим шанс на всеки български пациент да се лекува с най-добрите терапии.

slide 1
Giles Platford, Zurich, Switzerland

President, Europe & Canada, Takeda

We Won’t Rest until our innovative medicines are made available to all eligible cancer patients worldwide.

slide 1
Marc-Antoine Lucchini, France

Head of Europe Diabetes & Cardiovascualr Business Units, Sanofi

#WeWontRest until we have found a cure for Type 1 Diabetes.

slide 1
Karin Hagen, Sweden

Brand Manager, AbbVie

Director Medical Affairs Infectious Diseases, MSD.

slide 1
Johan Van Hoof, The Netherlands

Global Head, Janssen Vaccines, Janssen

#WeWontRest until we develop transformational vaccines to prevent, intercept, treat and cure life-threatening infectious diseases.

slide 1
Nicoletta Luppi, Italy

Managing Director Italy, MSD

#WeWontRest until every cancer patient can return to a normal life.

slide 1
Dr. Joern-Peter Halle, Germany

Head of External Innovation, Merck

As precision medicine opens new doors in the treatment of cancer, we must overcome challenges in finding the right patient for the right treatment. #WeWontRest until patients can be considered for multiple trials on the basis of a single molecular screening. 

slide 1
Isabel Paredes, Spain

Head of Clinical Research, Grupo Menarini España

We won't rest in research to develop new drugs that can cure diseases that still do not have effective solutions.

slide 1
Victoria Black, UK

Brand Manager, AbbVie

#WeWontRest until hepatitis C is eliminated.

slide 1
Hugo Fry, UK

General Manager, Sanofi UK, Sanofi

#WeWontRest until we live in a world in which no one suffers or dies from a vaccine-preventable disease.

slide 1
Lisa Deschamps

Worldwide Head Neuroscience, Novartis

#WeWontRest. Migraine matters and we are committed to working with the migraine community to discover new ways to improve people’s lives and give patients the voice they deserve.

slide 1
Nathalie Moll, Belgium

Director General, EFPIA

#WeWontRest until we unlock data sets all over Europe that will drive research and shape more effective patient care.

slide 1
Hilde Vanaken

R&D Operations Innovation Director, Janssen

I won’t rest until patients can use their smartphones to give us trial feedback in real time.

slide 1
Rachel Frizberg

Head of Commercial and Innovation, Roche Region Europe

#WeWontRest until we have the best teams working together to find new innovative therapies that help patients live longer and healthier lives.

slide 1
Cathryn Clary

Global Head Patient Affairs and Policy, Chief Medical Office, Novartis

#WeWontRest until we include patient insights in the planning of every clinical program.

slide 1
Martin Munte, Austria

President (Pharmig)/ CEO (Amgen Austria), Pharmig/Amgen Austria

#WeWontRest to support and conduct clinical trials until diseases have lost their negative impact on human lives.

slide 1
Nuria de Diego , Spain

Hepatitis C Brand Team Leader, AbbVie

We have advanced science and medicine to provide a cure for Hepatitis C and #WeWontRest until we have eliminated it.

slide 1
Pascale Mauran, France

Vice President Commercial Development, International Developed Markets, Pfizer

#WeWontRest until not one person loses their life to a vaccine-preventable illness.

slide 1
Danny Bar-Zohar

Global Head, Neuroscience Development, Novartis

#WeWontRest until we bring new advances and pioneering therapies in migraine to the patients that need them the most worldwide.

slide 1
Thomas B. Cueni, Switzerland

Director General, IFPMA

#WeWontRest until health is embedded in all policies, to achieve healthier lives at all ages and stages, wherever we live.

slide 1
Neil Barnes

Respiratory Global Franchise Medical Head, GSK

 #WeWontRest until we have helped asthma patients to #LiveEveryBreath. 

slide 1
Karolina Danysz

Pharmacovigilance Innovation Senior Specialist, Global Drug Safety & Risk Management, Celgene

#WeWontRest while opportunities exist to leverage innovative technologies to ensure the safety and wellbeing of our patients.

slide 1
Gema García Ledo, Spain

Oncology Head of Medical Affairs, AbbVie

#WeWontRest in our objective to transform the way cancer is treated allowing patients to achieve better health results and better quality of life.

slide 1
Emmanuel Canet

Senior Executive Vice-President Research and Development, Servier

#WeWontRest in our Research efforts to bring innovative medicines that makes a real difference to all patients’ lives.

slide 1
Virginia Zumárraga, Spain

Patient Experience Solution Lead, Immunology Patient Value Unit, UCB

 #WeWontRest until we incorporate the patient voice in the treatment decision making process and ensure patients as key stakeholders.

slide 1
Walter Mei, Italy

Value and Access Lead, Sanofi Genzyme

#WeWontRest until diagnosis becomes easier for every disease.

slide 1
Emmanuel Hanon

SVP – Head of Research & Development, GSK Vaccines

#WeWontRest until we have helped eradicate all vaccine-preventable diseases.

slide 1
Lisa Broad, UK

Senior Director, Pain Discovery UK, Lilly

The World Health Organisation (WHO) places migraine as the top 10 of the most disabling diseases. #WeWontRest until migraine becomes a manageable condition.

slide 1
Allan Hillgrove, Germany

Member of the Board of Managing Directors, Boehringer Ingelheim

#WeWontRest to ensure that our medicines, clinical trials and services meet the expectations of patients and patient organisations.

slide 1
John Young

Group President, Innovative Health, Pfizer

#WeWontRest until insights from individual patient experiences of living with and managing disease are built into every part of the lifecycle of our medicines and vaccines.

slide 1
Jörg Möller, Germany

Head of Research & Development, Bayer

#WeWontRest in our endeavor to find innovative solutions that make a difference in the lives of patients affected by serious medical conditions.

slide 1
Tracy-Jane Bailey-Burnley, Switzerland

Head of Marketing SMA, Europe & Canada, Biogen

#WeWontRest until all of the outstanding unmet need across the spectrum of SMA disease is addressed and the full impact of treatment is fully understood.

slide 1
Terttu Haring, The Netherlands/France

Global Head for Trial Operations, Sanofi

#WeWontRest until we make it possible for every eligible patient to participate in a clinical trial – irrespective their location, socio-economic status, age, mobility - and we make this participation an all-round positive experience for them.

slide 1
Frederic Clais, Belgium

Country Manager Belgium/Luxembourg, Lilly

Alzheimer’s: forgetting what was so obvious before. We continue to strive to find a treatment that modifies the course of the disease and #WeWontRest until we do so.